Point72 Hong Kong’s Editas Medicine EDIT Stock Holding History

Point72 Hong Kong’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-500	Closed	-$5.07K	–	611
2023 Q4	$5.07K	Buy	+500	New	+$4.39K	﹤0.01%	576
2022 Q4	–	Sell	-20,224	Closed	-$248K	–	554
2022 Q3	$248K	Buy	+20,224	New	+$315K	0.01%	987
2022 Q1	–	Sell	-2,935	Closed	-$78K	–	1970
2021 Q4	$78K	Buy	+2,935	New	+$101K	﹤0.01%	1241
2021 Q3	–	Sell	-7,023	Closed	-$398K	–	2097
2021 Q2	$398K	Buy	7,023 +5,036	+253%	+$186K	0.01%	981
2021 Q1	$83K	Buy	1,987 +875	+79%	+$49.8K	﹤0.01%	1190
2020 Q4	$78K	Sell	1,112 -113	-9%	-$4.64K	﹤0.01%	1122
2020 Q3	$34K	Buy	+1,225	New	+$39.9K	﹤0.01%	755
2020 Q1	–	Sell	-125	Closed	-$4K	–	1050
2019 Q4	$4K	Buy	+125	New	+$3.12K	﹤0.01%	1051
2018 Q4	–	Sell	-1,461	Closed	-$46K	–	968
2018 Q3	$46K	Buy	+1,461	New	+$47.2K	0.02%	479
2018 Q2	–	Sell	-1,232	Closed	-$41K	–	961
2018 Q1	$41K	Buy	+1,232	New	+$43.9K	0.02%	502

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Hong Kong's EDIT Position: Q1 2024 in Review

Point72 Hong Kong sold out of Editas Medicine (EDIT) in Q1 2024, closing a stake of 500 shares — an estimated $5.07K sold.

Point72 Hong Kong first reported a position in EDIT in Q1 2018 and held it in 10 quarters. The position peaked at $398K in Q2 2021. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.

Point72 Hong Kong reported no remaining Editas Medicine position as of Q1 2024 after selling out during the quarter.
Point72 Hong Kong sold 500 Editas Medicine shares in Q1 2024, an estimated $5.07K.
Point72 Hong Kong first reported a position in Editas Medicine in Q1 2018 and held it in 10 quarters.
Point72 Hong Kong's Editas Medicine position peaked at $398K in Q2 2021.
225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.

Based on Point72 Hong Kong's 13F filing for Q1 2024, filed 15 May 2024.